In a similar vein, preclinical studies confirm synergistic activity with BCL-2 and FLT3 inhibition57 with a phase 1b trial of venetoclax with gilteritinib in relapsed/refractory AML in progress. Here, FLT3 is linked to acute myeloid leukemia.